
<DOC>
<DOCNO>WT02-B10-7</DOCNO>
<DOCOLDNO>IA038-000728-B004-94</DOCOLDNO>
<DOCHDR>
http://www.deprenyl.com:80/factsht.htm 208.129.179.70 19970111075721 text/html 7203
HTTP/1.0 200 OK
Server: Microsoft-IIS/2.0
Date: Sat, 11 Jan 1997 07:57:09 GMT
Content-Type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3O/DTD HTML//EN">

<html>
<head>
<title>Investor Fact Sheet</title>
<meta name="GENERATOR" content="Microsoft FrontPage 1.1">
<meta name="FORMATTER" content="Microsoft FrontPage 1.1">
</head>
<body background="images/Paper12l.jpg" bgcolor="#FFFFFF"
text="#000000" link="#FF0000" vlink="#400080" alink="#FFFF00">
<h1 align="center">Investor Fact Sheet</h1>
<hr>
<p align="center"><img src="images/dahi_log.gif" align="bottom"
width="205" height="46"><br>
<br>
<b>A wholly-owned subsidiary of Draxis Health Inc.<br>
</b><font size="2"><b>(TSE: DAX; NASDAQ: DRAXF)</b></font></p>
<p>Deprenyl Animal Health, Inc. is a veterinary pharmaceutical
company established to commercialize the pharmaceutical Anipryl<sup><font
size="1">&#174;</font></sup> for use in veterinary medicine. </p>
<hr>
<h3>TABLE OF CONTENTS:</h3>
<ul>
    <li><a href="#Company">The Company</a> </li>
    <li><a href="#Status">Development Status</a> </li>
    <li><a href="#Market">The Market</a> </li>
    <li><a href="#Strategic">Strategic Alliances</a> </li>
    <li><a href="#Property">Intellectual Property</a> </li>
    <li><a href="#Manage">Management</a> </li>
    <li><a href="#Info">For Additional Information</a> </li>
</ul>
<hr>
<h3>The <a name="Company">Company</a></h3>
<p>Deprenyl Animal Health, Inc. (DAHI), a veterinary
pharmaceutical company, is engaged in obtaining worldwide
pre-marketing regulatory approval to commercialize Anipryl<sup><font
size="1">&#174;</font></sup> (l-selegiline hydrochloride), a
breakthrough therapy for treating canine senility or cognitive
dysfunction syndrome (also recognized as geriatric-onset
behavioral disorders) and Cushing's disease in pet dogs.
Geriatrics is a rapidly expanding and profitable sector of small
animal veterinary medicine. </p>
<p>DAHI received Canadian regulatory approval in September, 1995
for treating Cushing's disease with Anipryl<sup><font size="1">&#174;</font></sup>.
Canadian sales commenced in April, 1996, through DAHI's Canadian
distribution partner, Draxis Health Inc. </p>
<p>Since DAHI's March, 1991 IPO several other significant
milestones have been attained including the issuance of seven (7)
U.S. patents and the allowance of two (2) European patents, the
first regulatory approval for Anipryl<sup><font size="1">&#174;</font></sup>
(Canada), and the filing of its first completed application for
regulatory approval of Anipryl<sup><font size="1">&#174;</font></sup>
at the U.S. FDA. </p>
<hr>
<h3>Development <a name="Status">Status</a></h3>
<p>Currently, no other drugs are approved for treating canine
Cushing's disease or canine senility (cognitive dysfunction
syndrome). </p>
<p><i>Cushing's Disease Label Claim</i></p>
<ul>
    <li>Canadian regulatory approval, September, 1995 </li>
    <li>Filed first U.S. FDA New Animal Drug Application in
        October 1995 (Cushing's disease) </li>
</ul>
<p><i>Canine Senility or Cognitive Dysfunction Syndrome Label
Claim</i> </p>
<ul>
    <li>Pet owners often refer to cognitive dysfunction as
        senility, old dog syndrome (old dog behavior problems)</li>
    <li>Alzheimer's-like pathology in the brains of some
        afflicted pet dogs</li>
    <li>Pivotal (Phase III equivalent) clinical trial expected to
        conclude during early 1997 </li>
    <li>Substantial market opportunity for pharmaceutical
        intervention</li>
</ul>
<hr>
<h3>The <a name="Market">Market</a></h3>
<ul>
    <li>U.S. pet owners have an estimated 55.7 million dogs </li>
    <li>7.2 million (13%) of U.S. pet dogs are 10 years of age or
        older </li>
    <li>An estimated 35.9 million U.S. households own at least
        one pet dog </li>
    <li>Pet owners spend in excess of $20 billion per year on
        their pets including food, medical care and other
        supplies - demonstrated willingness of veterinarians and
        pet owners to invest in new products for maintaining pet
        health </li>
    <li>70% of U.S. pet owners view their pet &quot;as a family
        member&quot; </li>
    <li>Estimated that 1.5 million old U.S. dogs are afflicted
        with canine cognitive dysfunction syndrome </li>
    <li>An estimated 165,000 new North American cases of canine
        Cushing's disease occur each year</li>
</ul>
<p align="center">&#160; </p>
<hr>
<h3><a name="Strategic">Strategic</a> Alliances</h3>
<table cellpadding="2" cellspacing="5" width="100%">
    <tr>
        <td valign="top" width="75%">DAHI signed an agreement
        with Draxis Health Inc. in January, 1996 providing a
        10-year exclusive distribution right in Canada to its
        veterinary pharmaceutical Anipryl<sup><font size="1">&#174;</font></sup>.
        DAHI is a wholly-owned subsidiary of Draxis.
        <p>&#160; </p>
        </td>
        <td valign="bottom" width="164"><img
        src="images/dahiprod.gif" align="top" width="164"
        height="109"> <font size="2"><strong>Anipryl&#174;
        Production Suite<br>
        (Mikart, Inc.)</strong></font> </td>
    </tr>
</table>
<hr>
<h3>Intellectual <a name="Property">Property</a></h3>
<ul>
    <li>Seven U.S. patents issued </li>
    <li>Two European patents allowed </li>
    <li>Several patents covering DAHI's label claims have issued
        in other countries </li>
    <li>Additional patent applications are pending worldwide</li>
</ul>
<hr>
<h3><a name="Manage">Manage</a>ment</h3>
<p>Martin Barkin, MD, Chairman of the DAHI Board; President &amp;
CEO of Draxis Health Inc.<br>
David R. Stevens, DVM, PhD, President &amp; Chief Executive
Officer<br>
William W. Ruehl, VMD, PhD, Vice President, Scientific Affairs<br>
Laura D. Sayler, Director, Finance &amp; Administration <br>
Robert Dixon, Director, Sales<br>
Michael R. Grogan, Consultant, Marketing<br>
Daniel E. Walker, Consultant, Manufacturing &amp; Regulatory
Affairs</p>
<hr>
<h3>For Additional <a name="Info">Info</a>rmation, contact:</h3>
<p>Laura D. Sayler<br>
Deprenyl Animal Health, Inc.<br>
10955 Lowell, Suite 710<br>
Overland Park, KS 66210<br>
(913) 338-2120, fax (913) 338-3804 </p>
<hr>
<p align="center">[ <a href="index.htm" target="_top">DAHI Home
Page</a> | <a href="frmvettp.htm" target="_top">Veterinarians</a>
| <a href="frmowntp.htm" target="_top">Pet Owners</a> | <a
href="frminvtp.htm" target="_top">Investors</a> ]</p>
<p align="center">[ <a href="about.htm">About DAHI</a> | <a
href="contents.htm" target="_top">Contents</a> | <a
href="contacts.htm">Contacts</a> | <a href="Links.htm">Links</a>
| <a href="Press.htm">Press Releases</a> | <a href="request.htm">Request
for Information</a> ]</p>
<hr>
<p><font size="2"><em>Send comments to DAHI webmaster: </em></font><a
href="mailto:dahimaster@deprenyl.com"><font size="2"><em>dahimaster@deprenyl.com</em></font></a><font
size="2"><em><br>
Copyright &#169; 1996 </em>Deprenyl Animal Health, Inc.<em> All
rights reserved.<br>
Revised: December 19, 1996.</em></font></p>
</body>
</html>
</DOC>